reactivating antitumor efficacy of anti-pd-1 therapy with mrx0518
Published 2 years ago • 56 plays • Length 1:12Download video MP4
Download video MP3
Similar videos
-
1:31
mrx0518 combination therapy meets primary efficacy endpoint ahead of enrollment completion
-
7:32
updates on mrx0518 pembro in patients with resistance to therapy
-
8:04
mrx0518 pembro in patients with resistance to therapy
-
1:53
mrx0518 modification of solid tumor microenvironment
-
1:38
future indications for mrx0518
-
2:12
phase 1 study of anti-pd-l1 durvalumab plus gefitinib in tki-naïve patients with egfr-mutant nsclc
-
1:27
where to go next with pembrolizumab and other anti-pd-1 therapies in head and neck cancer
-
3:36
medi5752: first-in-human trial of a novel pd-1 and ctla-4 bispecific checkpoint inhibitor
-
5:42
cv8102 alone or in combination with anti-pd-1 antibodies for patients with skin cancer
-
1:43
treating tumors with synb1891 to overcome anti-pd1 resistance
-
1:10
multicenter phase ii trial evaluates adapt-001 for resistant tumors, showing promising efficacy
-
13:59
understanding and overcoming resistance to anti-pd-1 immunotherapy in melanoma
-
0:46
enhancing pd-1 blockade in hepatocellular carcinoma
-
11:40
toxicities associated with anti–pd-1 immunotherapy
-
0:46
immune checkpoint inhibitors: recent progress and potential biomarkers - 3iv pd-l1 overexpression
-
3:53
garnet: dostarlimab, a pd-1 antibody in advanced solid tumors
-
1:26
moffitt medical minute (ep. 29) - anti-pd-1 therapy
-
10:14
neoantigen-targeted cd8 t-cell responses with pd-1 blockade therapy